File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Focal sclerosing glomerulopathy. Risk factors of progession and optimal mode of treatment

TitleFocal sclerosing glomerulopathy. Risk factors of progession and optimal mode of treatment
Authors
Issue Date1991
PublisherSpringer Verlag Dordrecht. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0301-1623
Citation
International Urology And Nephrology, 1991, v. 23 n. 6, p. 619-629 How to Cite?
AbstractFocal sclerosing glomerulopathy and especially focal segmental glomerulosclerosis (FSGS) have been recognized as a distinct clinical entity, however, there still exist controversies in terms of prognostic risk factors of progression and optimal mode of treatment. A total of 32 patients (2 with focal global sclerosis; FGS, the remainder with FSGS) were followed up for a mean period of 82 months (3-240 months). Fourteen presented with nephrotic syndrome and 18 had proteinuria with or without hypertension. Thirteen patients, all of whom except 1 were nephrotic, received steroid treatment with or without other immunosuppressive agents (cyclophosphamide/cyclosporin A/azathioprine). Three of the steroid-treated remained stable incomplete remission; 5 nephrotic non-responders had renal death. The mean slope of 1/creatinine versus time for steroid-treated and non-treated groups was -0.23 and -0.043, respectively (p = 0.04), suggesting that nephrotic range proteinuria might be prognostically important. However, for the population of FSGS/FGS as a whole, only the initial serum creatinine predicted renal survival (p = 0.001 by Cox's regression model). Hypertension and hypercholesterolaemia were not important variables by themselves. Nevertheless, we found that the 9 patients treated with antihyperlipidaemics (gemfibrozil/probucol/cholestyramine/maxEPA) fared better, mean slope being -0.023 versus -0.103 for non-treated, though not reaching statistical significance (p = 0.96). Controlled prospective study involving a larger number of patients might be worthwhile.
Persistent Identifierhttp://hdl.handle.net/10722/147899
ISSN
2015 Impact Factor: 1.292
2015 SCImago Journal Rankings: 0.506

 

DC FieldValueLanguage
dc.contributor.authorChan, PCKen_US
dc.contributor.authorChan, KWen_US
dc.contributor.authorCheng, IKPen_US
dc.contributor.authorChan, MKen_US
dc.date.accessioned2012-05-29T06:09:48Z-
dc.date.available2012-05-29T06:09:48Z-
dc.date.issued1991en_US
dc.identifier.citationInternational Urology And Nephrology, 1991, v. 23 n. 6, p. 619-629en_US
dc.identifier.issn0301-1623en_US
dc.identifier.urihttp://hdl.handle.net/10722/147899-
dc.description.abstractFocal sclerosing glomerulopathy and especially focal segmental glomerulosclerosis (FSGS) have been recognized as a distinct clinical entity, however, there still exist controversies in terms of prognostic risk factors of progression and optimal mode of treatment. A total of 32 patients (2 with focal global sclerosis; FGS, the remainder with FSGS) were followed up for a mean period of 82 months (3-240 months). Fourteen presented with nephrotic syndrome and 18 had proteinuria with or without hypertension. Thirteen patients, all of whom except 1 were nephrotic, received steroid treatment with or without other immunosuppressive agents (cyclophosphamide/cyclosporin A/azathioprine). Three of the steroid-treated remained stable incomplete remission; 5 nephrotic non-responders had renal death. The mean slope of 1/creatinine versus time for steroid-treated and non-treated groups was -0.23 and -0.043, respectively (p = 0.04), suggesting that nephrotic range proteinuria might be prognostically important. However, for the population of FSGS/FGS as a whole, only the initial serum creatinine predicted renal survival (p = 0.001 by Cox's regression model). Hypertension and hypercholesterolaemia were not important variables by themselves. Nevertheless, we found that the 9 patients treated with antihyperlipidaemics (gemfibrozil/probucol/cholestyramine/maxEPA) fared better, mean slope being -0.023 versus -0.103 for non-treated, though not reaching statistical significance (p = 0.96). Controlled prospective study involving a larger number of patients might be worthwhile.en_US
dc.languageengen_US
dc.publisherSpringer Verlag Dordrecht. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0301-1623en_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshCyclosporine - Administration & Dosageen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlomerulosclerosis, Focal Segmental - Complications - Diagnosis - Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshKidney Function Testsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNephrotic Syndrome - Etiology - Therapyen_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective Studiesen_US
dc.titleFocal sclerosing glomerulopathy. Risk factors of progession and optimal mode of treatmenten_US
dc.typeArticleen_US
dc.identifier.emailChan, KW:hrmtckw@hku.hken_US
dc.identifier.authorityChan, KW=rp00330en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1769795-
dc.identifier.scopuseid_2-s2.0-0026325207en_US
dc.identifier.volume23en_US
dc.identifier.issue6en_US
dc.identifier.spage619en_US
dc.identifier.epage629en_US
dc.publisher.placeNetherlandsen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats